OpGen

OpGen Net Debt / EBITDA

The Net Debt to EBITDA of OpGen (OPGN) as of Oct 19, 2026 is 0.05. In the previous year, Net Debt to EBITDA was -0.76 — a change of -107.23% (higher).

Net Debt / EBITDA

0.05

YoY

-107.23%

Last updated:

Net Debt to EBITDA of OpGen is 2025 0.05 . Net Debt to EBITDA of OpGen was 2024 -0.76 . It decreases by -107.23% higher compared to the previous year.

The OpGen Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
0.04 USD
Jan 1, 2018
0.20 USD
Jan 1, 2019
-0.17 USD
Jan 1, 2020
-0.44 USD
Jan 1, 2021
0.47 USD
Jan 1, 2022
-0.33 USD
Jan 1, 2023
-0.76 USD
Jan 1, 2025
0.05 USD
The OpGen Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.05-107.23%
-0.76+127.63%
-0.33-171.09%
0.47-206.12%
-0.44+164.44%
-0.17-182.18%
0.20+461.54%
0.04-75.11%
0.15-65.85%
0.43-195.10%
-0.45-288.68%
0.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Net Debt to EBITDA of OpGen is 0.05 in 2025.

Net Debt to EBITDA of OpGen changed from -0.76 to 0.05, representing a -107.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA OpGen since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — OpGen

All Key Metrics — OpGen